Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology

Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology

Prostate-Specific Membrane Antigen (PSMA) is a highly expressed and structurally unique target specific to prostate cancer (PCa). Diagnostic and therapeutic approaches in nuclear medicine, coupling PSMA ligands with radionuclides, have shown significant clinical success. PSMA-PET/CT effectively iden...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhongji Jiang, Gaohaer Kadeerhan, Jin Zhang, Wenmin Guo, Hong Guo, Dongwen Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	prostate cancer (PCa) prostate-specific membrane antigen (PSMA) near-infrared/shortwave infrared (NIR/SWIR) targeted imaging fluorescence-guided surgery (FGS) radioligand therapy (RLT)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1533532/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia
by: Moritz B. Bastian, et al.
Published: (2025-07-01)

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)

Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-to-date overview based on the Global Burden of Disease 2021
by: Gaohaer Kadeerhan, et al.
Published: (2025-08-01)

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
by: Aaron R. Hansen, et al.
Published: (2025-01-01)

Exploration of linear and interpretable models for quantification of cell parameters via contactless short-wave infrared hyperspectral sensing
by: Anjana Hevaganinge, et al.
Published: (2025-01-01)

Global Shutter and Charge Binning With Quantum Dots Photodiode Arrays for NIR Imaging
by: Loic Baudoin, et al.
Published: (2024-01-01)

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01)

“Crossbreeding” NIR‐II flavchromene for PSMA‐positive prostate cancer detection and image‐guided surgery
by: Jialiang Huang, et al.
Published: (2024-09-01)

Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model
by: Meryl Maria Vilangattil, et al.
Published: (2025-03-01)

Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review
by: Ziye Wang, et al.
Published: (2025-07-01)

Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach
by: Jin Zhang, et al.
Published: (2025-05-01)

Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview
by: Antonela Njavro, et al.
Published: (2024-01-01)

[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production
by: Michela Aurilio, et al.
Published: (2025-05-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Random Forest-Based Retrieval of XCO<sub>2</sub> Concentration from Satellite-Borne Shortwave Infrared Hyperspectral
by: Wenhao Zhang, et al.
Published: (2025-02-01)

Enhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis
by: Jiang Z, et al.
Published: (2025-08-01)

Advancements and Challenges in Colloidal Quantum Dot Infrared Photodetectors: Strategies for Short-Wave Infrared, Mid-Wave Infrared, and Long-Wave Infrared Applications
by: Lijing Yu, et al.
Published: (2025-03-01)

Silicon Based GeSn p-i-n Photodetector for SWIR Detection
by: Hui Cong, et al.
Published: (2016-01-01)

Enhanced hgte quantum dots/silicon heterojunction mwir photodetector with porous contact surface
by: Amirhossein Ebadiyan, et al.
Published: (2025-09-01)

157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy
by: Liang Xie, et al.
Published: (2025-02-01)

A Trap-Assisted Photomultiplication-Type Organic Photodetector With High Detectivity From Visible to Shortwave Infrared Light
by: Jingwen Chen, et al.
Published: (2025-01-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

PSMA PET/CT scan reveals incidental meningioma in a prostate cancer patient
by: Venetia A. Florou, et al.
Published: (2025-05-01)

Features of Visual Dysfunctions in Patients with Primary Hypothyroidism and Thyrotoxicosis
by: V. G. Likhvantseva, et al.
Published: (2022-10-01)

Photonics Breakthroughs 2024: Advances in Heavy-Metal-Free Quantum Dot Shortwave Infrared Photodetectors and Image Sensors: The Case of Ag<sub>2</sub>Te QDs
by: Yongjie Wang, et al.
Published: (2025-01-01)

<sup>225</sup>Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer
by: T. Yu. Kochetova, et al.
Published: (2025-01-01)

Efficacy of <sup>177</sup>Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
by: Ebuzer Kalender, et al.
Published: (2025-02-01)

Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11
by: Jianpeng Cao, et al.
Published: (2025-06-01)

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)

Investigating the significance of SPECT/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review
by: Tahani O. Alkahtani
Published: (2025-01-01)

Evaluation the Electronic Properties of Glu-Ureido Template via Ab-Initio Study as Target Specific for PSMA
by: Mohd. Faheem, et al.
Published: (2024-11-01)

Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era
by: Juan Gómez Rivas, et al.
Published: (2025-05-01)

Intra-Individual Comparisons of [18F]fluorodeoxyglucose and Prostate-Specific Membrane Antigen Positron Emission Tomography in Prostate Cancer Patients Across Different Disease States: New Insights into Disease Heterogeneity
by: Stephen McGeorge, et al.
Published: (2024-12-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

PSMA PET/CT for prostate cancer diagnosis: current applications and future directions
by: Zhengang Shen, et al.
Published: (2025-05-01)

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer
by: Anna-Lena Zang, et al.
Published: (2025-09-01)

The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival
by: L.M. Altus, et al.
Published: (2025-06-01)

Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022
by: D. A. Andreev, et al.
Published: (2022-06-01)

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study
by: Sofía González-Rueda, et al.
Published: (2024-10-01)

Using low-molecular-weight ligands for targeting in integrated chemodynamic/starvation therapy and chemotherapy for prostate cancer
by: Xiaoli Zhang, et al.
Published: (2025-06-01)